Scholarlink

Purpose <p>Does fertility preservation (FP) through oocyte cryopreservation provide realistic reproductive opportunities for diminished ovarian reserve (DOR)? Literature suggests cumulative live birth rates of 30–45% with 8–10 oocytes under 35&#xa0;years old. Insufficient data exist to define whether DOR patients should be offered FP systematically.</p> Methods <p>This retrospective single-center study analyzed data from 304 women undergoing oocyte cryopreservation (January 2016–December 2024). Patients were stratified into cohort 1 (Anti-Müllerian hormone—AMH—≤ 0.5&#xa0;ng/mL, <i>n</i> = 49) and cohort 2 (AMH &gt; 0.5&#xa0;ng/mL, <i>n</i> = 255). Primary outcomes included retrieved oocytes (RO) and vitrified oocytes (VO). Secondary outcome examined DuoStim results. Statistical analysis included correlation assessments, ANCOVA, and multiple linear regression.</p> Results <p>DOR patients achieved lower oocyte yields compared to cohort 2 (RO: 3.1 ± 2.3 vs. 9.0 ± 6.5; VO: 2.3 ± 1.9 vs. 7.4 ± 5.1; <i>p</i> &lt; 0.001), despite higher gonadotropin doses. AMH strongly correlated with RO (<i>ρ</i> = 0.636, <i>p</i> &lt; 0.001) and VO (<i>ρ</i> = 0.624, <i>p</i> &lt; 0.001). Linear regression confirmed AMH (<i>B</i> = 1.151, <i>p</i> &lt; 0.001) and age (<i>B</i> =  − 0.139, <i>p</i> = 0.002) as significant predictors of VO. In DuoStim subgroup, DOR patients achieved 3.3 ± 2.1 total VO compared to 6.9 ± 3.3 in cohort 2 (<i>p</i> = 0.001).</p> Conclusion <p>DOR patients achieve oocyte yields substantially below thresholds associated with reasonable live birth rates, raising concerns regarding FP efficacy. These findings highlight the need for personalized counseling that considers individual patient characteristics and provides evidence-based, realistic expectations for FP. A revision of current AMH thresholds may improve patient selection and cost-effectiveness of FP programs. Younger DOR patients may benefit from oocyte cryopreservation for FP, emphasizing the importance of age stratification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fertility preservation in women with diminished ovarian reserve: evaluating the AMH criteria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月26日

查看全文
  • Maria Elisabetta Coccia,
  • Benedetta Gabbrielli,
  • Giulia Cutajar,
  • Francesca Piazzini,
  • Paolo Evangelisti,
  • Laura Badolato,
  • Patrizia Falcone,
  • Rossella Fucci,
  • Carlo Bulletti

摘要

Purpose

Does fertility preservation (FP) through oocyte cryopreservation provide realistic reproductive opportunities for diminished ovarian reserve (DOR)? Literature suggests cumulative live birth rates of 30–45% with 8–10 oocytes under 35 years old. Insufficient data exist to define whether DOR patients should be offered FP systematically.

Methods

This retrospective single-center study analyzed data from 304 women undergoing oocyte cryopreservation (January 2016–December 2024). Patients were stratified into cohort 1 (Anti-Müllerian hormone—AMH—≤ 0.5 ng/mL, n = 49) and cohort 2 (AMH > 0.5 ng/mL, n = 255). Primary outcomes included retrieved oocytes (RO) and vitrified oocytes (VO). Secondary outcome examined DuoStim results. Statistical analysis included correlation assessments, ANCOVA, and multiple linear regression.

Results

DOR patients achieved lower oocyte yields compared to cohort 2 (RO: 3.1 ± 2.3 vs. 9.0 ± 6.5; VO: 2.3 ± 1.9 vs. 7.4 ± 5.1; p < 0.001), despite higher gonadotropin doses. AMH strongly correlated with RO (ρ = 0.636, p < 0.001) and VO (ρ = 0.624, p < 0.001). Linear regression confirmed AMH (B = 1.151, p < 0.001) and age (B =  − 0.139, p = 0.002) as significant predictors of VO. In DuoStim subgroup, DOR patients achieved 3.3 ± 2.1 total VO compared to 6.9 ± 3.3 in cohort 2 (p = 0.001).

Conclusion

DOR patients achieve oocyte yields substantially below thresholds associated with reasonable live birth rates, raising concerns regarding FP efficacy. These findings highlight the need for personalized counseling that considers individual patient characteristics and provides evidence-based, realistic expectations for FP. A revision of current AMH thresholds may improve patient selection and cost-effectiveness of FP programs. Younger DOR patients may benefit from oocyte cryopreservation for FP, emphasizing the importance of age stratification.